Knockdown of TFPI-2 promotes migration and invasion of glioma cells

被引:46
作者
Gessler, Florian [1 ]
Voss, Valerie [1 ]
Seifert, Volker [2 ]
Gerlach, Ruediger [2 ]
Koegel, Donat [1 ]
机构
[1] Goethe Univ Hosp, Ctr Neurosci, D-60590 Frankfurt, Germany
[2] Goethe Univ Hosp, Dept Neurosurg, D-60590 Frankfurt, Germany
关键词
Brain tumor; Tumor suppressor; Tumor microenvironment; ECM degradation; Cell proliferation; MMPs; FACTOR PATHWAY INHIBITOR-2; EXPRESSION; CDNA;
D O I
10.1016/j.neulet.2011.04.027
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Glioblastoma is the most malignant primary brain tumor. Due to its highly promigratory and proinvasive properties, standard therapy including surgery, chemotherapy and radiation fails in eradicating this highly aggressive type of cancer. Here, we evaluated the role of TFPI-2, a Kunitz-type serine protease inhibitor, which has been previously described as a tumor suppressor gene in several types of cancer, including glioma. TFPI-2 expression was absent in five of nine investigated high-grade glioma cell lines. Lentiviral knockdown of TFPI-2 in two of the TFPI-2-expressing cell lines (MZ-18 and Hs 638) was associated with pronounced changes in the cellular behavior: glioma cell proliferation, migration and invasion were significantly increased in TFPI-2 knockdown cells in comparison to empty vector-transfected control cells. Since TFPI-2 might exert its tumor suppressor function by inhibiting MMPs, we subsequently analyzed the effects of specific MMP inhibitors on cell invasion of TFPI-2 KD cells vs. control cells. The data obtained from these experiments suggest that the anti-invasive properties of TFPI-2 are associated with inhibition of MMP-1 and MMP-2, while inhibition of MMP-9 seems to play a minor role in this context. Our findings underscore the important role of TFPI-2 as a tumor suppressor gene and indicate that TFPI-2 may be a useful diagnostic marker for the aggressive phenotype of glial tumors. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 28 条
[1]   NUCLEOSOME STRUCTURAL-CHANGES DUE TO ACETYLATION [J].
BAUER, WR ;
HAYES, JJ ;
WHITE, JH ;
WOLFFE, AP .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 236 (03) :685-690
[2]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107
[3]  
DECLERCK YA, 1994, J NEURO-ONCOL, V18, P111
[4]   Human tissue factor pathway inhibitor-2 does not bind or inhibit activated matrix metalloproteinase-1 [J].
Du, X ;
Chand, HS ;
Kisiel, W .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2003, 1621 (03) :242-245
[5]   Restoraton of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis [J].
George, Joseph ;
Gondi, Christopher S. ;
Dinh, Dzung H. ;
Gujrati, Meena ;
Rao, Jasti S. .
CLINICAL CANCER RESEARCH, 2007, 13 (12) :3507-3517
[6]   INHIBITION OF TISSUE FACTOR/PROTEASE-ACTIVATED RECEPTOR-2 SIGNALING LIMITS PROLIFERATION, MIGRATION AND INVASION OF MALIGNANT GLIOMA CELLS [J].
Gessler, F. ;
Voss, V. ;
Duetzmann, S. ;
Seifert, V. ;
Gerlach, R. ;
Koegel, D. .
NEUROSCIENCE, 2010, 165 (04) :1312-1322
[7]   Glioma invasion in the central nervous system [J].
Giese, A ;
Westphal, M .
NEUROSURGERY, 1996, 39 (02) :235-250
[8]   Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis [J].
Herman, MP ;
Sukhova, GK ;
Kisiel, W ;
Foster, D ;
Kehry, MR ;
Libby, P ;
Schönbeck, U .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (09) :1117-1126
[9]   Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion [J].
Iochmann, Sophie ;
Blechet, Claire ;
Chabot, Valerie ;
Saulnier, Annabelle ;
Amini, Anica ;
Gaud, Guillaume ;
Gruel, Yves ;
Reverdiau, Pascale .
CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (05) :457-467
[10]   Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), in human glioma cells [J].
Konduri, SD ;
Srivenugopal, KS ;
Yanamandra, N ;
Dinh, DH ;
Olivero, WC ;
Gujrati, M ;
Foster, DC ;
Kisiel, W ;
Ali-Osman, F ;
Kondraganti, S ;
Lakka, SS ;
Rao, JS .
ONCOGENE, 2003, 22 (29) :4509-4516